Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
INFI's Cash to Debt is ranked higher than
90% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. INFI: No Debt )
INFI' s 10-Year Cash to Debt Range
Min: 0.28   Max: 13254
Current: No Debt

0.28
13254
Equity to Asset 0.62
INFI's Equity to Asset is ranked higher than
70% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INFI: 0.62 )
INFI' s 10-Year Equity to Asset Range
Min: -0.03   Max: 0.94
Current: 0.62

-0.03
0.94
F-Score: 5
Z-Score: 3.32
M-Score: 1.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -1.18
INFI's Operating margin (%) is ranked higher than
83% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. INFI: -1.18 )
INFI' s 10-Year Operating margin (%) Range
Min: -6986.21   Max: 22.94
Current: -1.18

-6986.21
22.94
Net-margin (%) -6.22
INFI's Net-margin (%) is ranked higher than
81% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. INFI: -6.22 )
INFI' s 10-Year Net-margin (%) Range
Min: -6967.24   Max: 28.35
Current: -6.22

-6967.24
28.35
ROE (%) -5.06
INFI's ROE (%) is ranked higher than
83% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. INFI: -5.06 )
INFI' s 10-Year ROE (%) Range
Min: -123.36   Max: 27.59
Current: -5.06

-123.36
27.59
ROA (%) -3.99
INFI's ROA (%) is ranked higher than
84% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. INFI: -3.99 )
INFI' s 10-Year ROA (%) Range
Min: -51.92   Max: 16.29
Current: -3.99

-51.92
16.29
ROC (Joel Greenblatt) (%) -52.20
INFI's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. INFI: -52.20 )
INFI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3156.78   Max: 338.58
Current: -52.2

-3156.78
338.58
Revenue Growth (3Y)(%) -100.00
INFI's Revenue Growth (3Y)(%) is ranked higher than
54% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. INFI: -100.00 )
INFI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 155.9
Current: -100

0
155.9
EBITDA Growth (3Y)(%) 12.80
INFI's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. INFI: 12.80 )
INFI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.6   Max: 261.4
Current: 12.8

-64.6
261.4
EPS Growth (3Y)(%) 12.40
INFI's EPS Growth (3Y)(%) is ranked higher than
87% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. INFI: 12.40 )
INFI' s 10-Year EPS Growth (3Y)(%) Range
Min: -64   Max: 115.9
Current: 12.4

-64
115.9
» INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

INFI Guru Trades in Q4 2013

Jim Simons 763,600 sh (+267.82%)
Steven Cohen 3,555,500 sh (-13.17%)
» More
Q1 2014

INFI Guru Trades in Q1 2014

John Burbank 16,556 sh (New)
Steven Cohen 3,411,659 sh (-4.05%)
Jim Simons 498,540 sh (-34.71%)
» More
Q2 2014

INFI Guru Trades in Q2 2014

Chuck Royce 123,400 sh (New)
Steven Cohen 3,410,978 sh (unchged)
John Burbank Sold Out
Jim Simons 198,600 sh (-60.16%)
» More
Q3 2014

INFI Guru Trades in Q3 2014

Paul Tudor Jones 16,163 sh (New)
Chuck Royce 135,400 sh (+9.72%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 1,700,000 sh (-50.16%)
Jim Simons 42,800 sh (-78.45%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-06-30 Sold Out 0.01%$8.6 - $12.67 $ 17.7371%0
John Burbank 2014-03-31 New Buy0.01%$11.37 - $16.52 $ 17.7332%16556
George Soros 2013-06-30 Sold Out 0.02%$16.192 - $50.09 $ 17.73-43%0
George Soros 2013-03-31 Reduce -46.67%0.01%$32.93 - $49.37 $ 17.73-55%40000
George Soros 2012-12-31 New Buy0.03%$17.74 - $35.04 $ 17.73-30%75000
Jean-Marie Eveillard 2012-06-30 Sold Out 0.01%$11.71 - $13.76 $ 17.7339%0
Jean-Marie Eveillard 2012-03-31 Reduce -54.94%0.01%$5.9781 - $12.16 $ 17.73123%180000
Jean-Marie Eveillard 2011-09-30 Reduce -25.85%0.01%$6.17 - $10.36 $ 17.73125%464241
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.51
INFI's P/B is ranked higher than
82% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. INFI: 3.51 )
INFI' s 10-Year P/B Range
Min: 0.68   Max: 51.23
Current: 3.51

0.68
51.23
P/S 5.49
INFI's P/S is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. INFI: 5.49 )
INFI' s 10-Year P/S Range
Min: 1.32   Max: 60.95
Current: 5.49

1.32
60.95
PFCF 7.09
INFI's PFCF is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INFI: 7.09 )
INFI' s 10-Year PFCF Range
Min: 2.17   Max: 48.64
Current: 7.09

2.17
48.64
EV-to-EBIT -255.73
INFI's EV-to-EBIT is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INFI: -255.73 )
INFI' s 10-Year EV-to-EBIT Range
Min: -266.1   Max: 493.6
Current: -255.73

-266.1
493.6
Current Ratio 6.69
INFI's Current Ratio is ranked higher than
80% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. INFI: 6.69 )
INFI' s 10-Year Current Ratio Range
Min: 0.64   Max: 17.81
Current: 6.69

0.64
17.81
Quick Ratio 6.69
INFI's Quick Ratio is ranked higher than
81% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. INFI: 6.69 )
INFI' s 10-Year Quick Ratio Range
Min: 0.41   Max: 17.81
Current: 6.69

0.41
17.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.79
INFI's Price/Net Cash is ranked higher than
92% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. INFI: 3.79 )
INFI' s 10-Year Price/Net Cash Range
Min: 0.87   Max: 38.43
Current: 3.79

0.87
38.43
Price/Net Current Asset Value 3.76
INFI's Price/Net Current Asset Value is ranked higher than
92% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. INFI: 3.76 )
INFI' s 10-Year Price/Net Current Asset Value Range
Min: 0.85   Max: 36.83
Current: 3.76

0.85
36.83
Price/Tangible Book 3.51
INFI's Price/Tangible Book is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. INFI: 3.51 )
INFI' s 10-Year Price/Tangible Book Range
Min: 0.74   Max: 46
Current: 3.51

0.74
46
Price/DCF (Projected) 10.55
INFI's Price/DCF (Projected) is ranked higher than
92% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INFI: 10.55 )
INFI' s 10-Year Price/DCF (Projected) Range
Min: 4.62   Max: 143.11
Current: 10.55

4.62
143.11
Price/Median PS Value 1.33
INFI's Price/Median PS Value is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. INFI: 1.33 )
INFI' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 14.47
Current: 1.33

0.36
14.47
Earnings Yield (Greenblatt) -0.40
INFI's Earnings Yield (Greenblatt) is ranked higher than
85% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. INFI: -0.40 )
INFI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 4271.1
Current: -0.4

0.2
4271.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I3F.Germany,
Infinity Pharmaceuticals, Inc. was incorporated in California on March 22, 1995 under the name IRORI and, in 1998; the Company changed its name to Discovery Partners International, Inc. On September 12, 2006, Discovery Partners completed a merger with Infinity Pharmaceuticals, Inc., to which a wholly-owned subsidiary of Discovery Partners merged with and into the Company. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to people with difficult-to-treat diseases. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. The IPI-145, its primary product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in white blood cells, where they have distinct and mostly non-overlapping roles in immune cell development and function. For Hematologic Malignancies, the Company has launched DUETTS, an investigation of IPI-145 in blood cancers. As part of the DUETTS program, it is conducting DYNAMO, a Phase 2, open-label, single arm study evaluating the safety and efficacy of IPI-145 dosed at 25mg BID in approximately 120 patients with indolent non-Hodgkin lymphoma, or iNHL, including follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma, whose disease is refractory to radio immunotherapy or both rituximab and chemotherapy. The FDA has granted orphan drug designation to IPI-145 for the potential treatment of follicular lymphoma. It is conducting DUO, a randomized, monotherapy Phase 3 study of IPI-145 in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia. For Inflammation and Autoimmune Diseases, the Company has completed a Phase 1, randomized, double-blind, placebo-controlled trial of IPI-145 in healthy adult subjects designed to support the development of IPI-145 in inflammatory and autoimmune diseases. The Company is also developing its second PI3K product candidate, a potent, oral inhibitor of PI3K-delta and gamma referred to as IPI-443. The nonclinical studies of IPI-443 required for Phase 1 development have been completed, and the data from the two Phase 2 studies of IPI-145 in inflammatory and autoimmune diseases will guide the next steps for the development of IPI-443. The Company has discovered IPI-940, a novel, orally available inhibitor of fatty acid amide hydrolase. It is believed that inhibition of FAAH may enable the body to bolster its own analgesic and anti-inflammatory response and may have applicability in a broad range of painful or inflammatory conditions. The Company has five issued or allowed U.S. patents covering IPI-145 and/or other molecules related to PI3K program, which expires on various dates between 2029 and 2031. In addition, it has approximately 170 patents and patent applications pending related to PI3K pro
» More Articles for INFI

Headlines

Articles On GuruFocus.com
comment on INFI Mar 02 2013 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Dec 19 2014
Disposal of hydro business for £20.5m Dec 19 2014
Form 8.3 - Infinis Energis Plc Dec 19 2014
Lightning Round: I want this to go lower Dec 15 2014
Response to Terra Firma announcement Dec 15 2014
Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at... Dec 09 2014
Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at... Dec 09 2014
Infinity Reports New Translational Research and Updated Phase 1 Data of Investigational Oncology... Dec 08 2014
Infinity Reports New Translational Research and Updated Phase 1 Data of Investigational Oncology... Dec 08 2014
Infinity Pharmaceuticals (INFI) Is Today's Strong On High Volume Stock Nov 26 2014
Infinity to Present at the Deutsche Bank Securities 2014 BioFEST Conference Nov 24 2014
Infinity to Present at the Deutsche Bank Securities 2014 BioFEST Conference Nov 24 2014
INFINITY PHARMACEUTICALS, INC. Financials Nov 18 2014
Infinity Pharmaceuticals (INFI) Upgraded From Sell to Hold Nov 14 2014
INFINITY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2014
Infinity beats 3Q profit forecasts Nov 06 2014
Infinity beats 3Q profit forecasts Nov 06 2014
Infinity Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Nov 06 2014
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 06 2014
Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK